This study was designed to investigate the presence of mutations in the pncA gene, minimum inhibitory concentrations and pyrazinamidase activity of pyrazinamideresistant Mycobacterium tuberculosis. In total, 47 M. tuberculosis clinical isolates from a local region of China were assayed. Pyrazinamidase activity was measured by pyrazinamide deamination to pyrazinoic acid and ammonia, and a 721 bp region, including the entire pncA open-reading frame, 104 bp of the upstream sequence and 59 bp of the downstream sequence, was determined by DNA sequencing of purified polymerase chain reaction products. Of the 47 isolates resistant to pyrazinamide, 44 lost pyrazinamidase activity and had pncA mutations that occurred mainly near pyrazinamidase's active or metal ion binding sites; nine of them have not been reported previously. Three pyrazinamide-resistant isolates carried the wild-type pncA sequence and retained pyrazinamidase activity. These results show the molecular mechanism of pyrazinamide resistance in China and may also contribute towards the prevention of tuberculosis in China.
Introduction
Tuberculosis (TB) still remains one of the leading causes of morbidity and mortality in the world, with China having the second highest rate worldwide. The World Health Organization reported that, in 2007, China had a TB incidence of 98 new cases per 100 000 population per year and a mortality rate of 15 cases per 100 000 population per year. 1 One of the major reasons for this high mortality rate is drug resistance, particularly the development of multi-drug resistance. Controlling TB has become more difficult with the emergence of drug-resistant Mycobacterium tuberculosis. 2 Pyrazinamide is an important first-line drug used for the short-course treatment of TB in combination with isoniazid and *H Zhang and L-J Bi contributed equally to this work. rifampin. It is responsible for killing persistent tubercle bacilli during the initial intensive phase of chemotherapy, allowing the treatment time to be shortened from 9 months to 6 months. 3, 4 Pyrazinamide is a prodrug that is converted to bactericidal pyrazinoic acid by pyrazinamidase produced by M. tuberculosis. Mutations in the pncA gene have been associated with pyrazinamide resistance in vitro. 5 Thus, the types and frequencies of mutations in the pncA gene of pyrazinamide-resistant clinical isolates from Hefei, Anhui Province, China, were characterized and are reported here. 
Materials and methods

MYCOBACTERIAL ISOLATES
PYRAZINAMIDE MICS
Pyrazinamide minimal inhibitory concentrations (MICs) were assayed by a modification of the proportion method on solid medium. 6, 7 Pyrazinamide concentrations of 25, 50, 100, 200, 400 and 800 µg/ml were tested in triplicate assays for each concentration. All isolates were tested twice.
PYRAZINAMIDASE ASSAY
Pyrazinamidase activity was assayed by a modification of the method developed by Wayne. 7, 8 Two tubes (10 ml/tube) of 7H10 medium containing 1 mg pyrazinamide and 20 mg sodium pyruvate were inoculated with each strain and incubated at 37°C. One tube was examined after 7 days of incubation and the other was examined after 14 days. After incubation, 1.0 ml of 1% ferrous ammonium sulphate was added to each tube and the tubes were held at 4°C for 4 h. A strain was considered positive for pyrazinamidase if a pink band was observed in the upper part of the agar butt. Each strain was compared with the positive (pyrazinamide-sensitive M. tuberculosis strain H37rv) and negative (M. bovis BCG Pasteur) controls. All the tubes were examined independently by three individuals.
GENOMIC DNA PREPARATION AND SEQUENCING
Chromosomal DNA was extracted from isolates cultured for 30 days at 37°C in Löwenstein-Jensen medium as described by Morlock et al. 7 A 721 bp region, including the entire pncA open-reading frame, 104 bp of the upstream sequence and 59 bp of the downstream sequence, was amplified by polymerase chain reaction (PCR) with forward primer pncA-10 (5′-GCTGGTCATG TTCGCGATCG-3′) and reverse primer pncA-11 (5′-GCTTTGCGGCGAGCGCTCCA-3′). 7 Each 50 µl reaction mixture contained 1.0 ng of template DNA, 200 µM of each deoxynucleotide triphosphate, 0.1 µM of each PCR primer and 1 U of Pyrobest™ DNA polymerase (Takara Biotechnology, Dalian, China). The PCR amplifications were carried out in a MyCycler TM thermocycler (Bio-Rad Laboratories, Foster City, CA, USA) with the following parameters: 94°C for 5 min, followed by 30 cycles of 1 min at 94°C, 1 min at 64°C and 1.5 min at 72°C, and a final extension for 10 min at 72°C. The PCR products were purified with a gel extraction kit (E.Z.N.A. ® , Omega Bio-Tek, GA, USA) according to the manufacturer's instructions.
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The purified PCR products were sequenced using rhodamine DyeDeoxy Terminator chemistry according to the manufacturer's protocol (PerkinElmer, Foster City, CA, USA) with primer pncA-11. The sequence data were analysed using Sequence Navigator software, version 1.0.1 (PerkinElmer) and the results were compared with the pncA published sequence (GenBank Accession No. U59967).
Results
A total of 47 pyrazinamide-resistant M.
tuberculosis clinical isolates (35 multi-drugresistant isolates and 12 isolates resistant only to pyrazinamide) that were negative for pyrazinamidase activity and, therefore, resistant to pyrazinamide (MIC ≥ 200 µg/ml), were chosen for the sequence analysis. Of these, 44 (93.6%) exhibited 29 different changes in the pncA gene compared with the wild-type (H37rv) sequence and lacked pyrazinamidase activity ( substitution among 33 isolates, one stop codon mutation found in one isolate, frameshift mutations caused by three deletions (158-201 deletion of 44 bp, 378-387 deletion of 10 bp, and 61 deletion G) in three isolates and by two insertions (391-392 insertion GG and 391 insertion G) in three isolates, and one promoter mutation (-11 A¦G) found in seven isolates.
The frequency of mutations in regions along the pncA gene is shown in Table 2 . In total, 60.8% of the mutations were located in the regions surrounding pyrazinamidase's active or metal ion binding sites, whilst 39.2% occurred in other regions.
Discussion
Since 93.6% of the M. tuberculosis clinical isolates exhibited 29 different changes in the pncA gene compared with the wild-type (H37rv) sequence and lacked pyrazinamidase activity, the results suggest that pncA mutation is a major contributor to pyrazinamide resistance in this region.
Nine of the mutations in pncA have not previously been reported, including five point mutations causing amino acid substitutions and four frameshift mutations causing premature terminations (except 391-392 insertion GG). 5,7 -28 In one isolate with a negative pyrazinamidase test, the only change found was a synonymous mutation, alanine (Ala) 36¦Ala, resulting in a GCC ¦ GCG codon variation. As there is codon preference in bacterial protein synthesis, it may be that the codon prefers GCC to GCG in M. tuberculosis Ala synthesis, leading to termination or reduction of protein synthesis.
Although previous studies have detailed several mutations leading to pyrazinamide resistance scattered along the pncA gene, our group in a previous experiment discovered a concentration of pncA mutations, at amino acid residues 3 -12, 46 -62, 68 -85, 94 -103 and 132 -142, that are areas near pyrazinamidase's active (C138, D8 and K96) and metal ion binding sites (D49, H51, H57 and H71) ( Table 2) . 29 Approximately 70% of mutations have previously been reported as located in the regions surrounding the pyrazinamidase's active and metal ion binding sites, 5,7 -28 but only 60.8% of mutations occurred in these regions in the present study, while 39.2% occurred in other regions. The fact that these strains were isolated in distinct regions in China suggests that environmental factors may influence the distribution of mutations along the pncA gene.
Different mechanisms of pyrazinamide resistance may exist. The pncA mutations in the 44 clinical M. tuberculosis isolates in the present study that lacked pyrazinamidase activity occurred mainly near pyrazinamidase's active or metal ion binding sites, which means they should be highly related to the loss of enzyme. Among the mutations, nine had not been reported previously. Three pyrazinamide-resistant strains that did not have any mutations in the pncA gene were identified in the present analysis, suggesting there are other M. tuberculosis genomic regions involved in resistance to pyrazinamide.
